for people ages 12-99 (full criteria)
at UC Davis
study started
estimated completion



The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

Official Title

A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo


Vitiligo, JAK Inhibitor, Non-segmental, hypopigmentation, Pigment Disorders, Skin Diseases, Ruxolitinib 1.5% cream, NB-UVB phototherapy, Ruxolitinib + Narrow-Band Ultraviolet B Phototherapy (NB-UVB), Ruxolitinib Monotherapy


You can join if…

Open to people ages 12-99

  • A clinical diagnosis of nonsegmental vitiligo with depigmented area including all of the following:
    1. ≥ 0.5 F-VASI on the face
    2. ≥ 3.0 T-VASI (body areas not including the face)
    3. Total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.
  • Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.

You CAN'T join if...

  • No pigmented hair within any of the vitiligo areas on the face.
  • Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders.
  • Used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.
  • Previous adverse reaction to NB-UVB phototherapy that caused discontinuation of therapy.
  • Lack of response (little or no repigmentation) to prior NB-UVB phototherapy.
  • History of thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, ischemic stroke, myocardial infarction).
  • Any other skin disease that, in the opinion of the investigator, would interfere with the study cream application or study assessments.
  • Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chicken pox) within 1 week before baseline.
  • Any serious illness or medical, physical, or psychiatric condition(s) that pose a significant risk to the participant; or interfere with interpretation of study data.
  • Recent use of topical or systemic medications (including biologics or JAK inhibitors), or laser or phototherapy to treat vitiligo. Note: Recent may be defined differently for different treatments.
  • Specific protocol-defined chemistry, hematology, and serological lab values.
  • Those who are pregnant, lactating or considering pregnancy during the period of study participation.


  • UC Davis Health
    Sacramento California 95816 United States
  • First Oc Dermatology
    Fountain Valley California 92708 United States


in progress, not accepting new patients
Start Date
Completion Date
Incyte Corporation
Phase 2 research study
Study Type
About 55 people participating
Last Updated